Evidence map›Paper›PMID 34484091›Full record

ArticleFrontiers in neurology2021

Monoacylglycerol Lipase Inhibitor MJN110 Reduces Neuronal Hyperexcitability, Restores Dendritic Arborization Complexity, and Regulates Reward-Related Behavior in Presence of HIV-1 Tat.

Alexis F League, Benjamin L Gorman, Douglas J Hermes, Clare T Johnson, Ian R Jacobs, Barkha J Yadav-Samudrala, Justin L Poklis, Micah J Niphakis, Benjamin F Cravatt, Aron H Lichtman and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Effects of acute ΔBrain research · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Alexis F LeagueDepartment of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, United States.
Benjamin L GormanDepartment of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, United States.
Douglas J HermesDepartment of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, United States.
Clare T JohnsonDepartment of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, United States.
Ian R JacobsDepartment of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, United States.
Barkha J Yadav-SamudralaDepartment of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, United States.
Justin L PoklisDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, United States.
Micah J NiphakisDepartment of Chemistry, Scripps Research Institute, La Jolla, CA, United States.
Benjamin F CravattDepartment of Chemistry, Scripps Research Institute, La Jolla, CA, United States.
Aron H LichtmanDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, United States.
Bogna M Ignatowska-JankowskaOkinawa Institute of Science and Technology, Neuronal Rhythms in Movement Unit, Okinawa, Japan.
Sylvia FittingDepartment of Psychology and Neuroscience, University of North Carolina Chapel Hill, Chapel Hill, NC, United States.
University of North Carolina at Chapel Hill · USScripps Research Institute · USVirginia Commonwealth University · USOkinawa Institute of Science and Technology Graduate University · JP

Funding

VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI JOLENE J WINDLE · 2014 to 2026
$13.8M
Training on Research in Drug AbuseT32DA007244 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Regina M Carelli · 1990 to 2026
$7.6M
CB1 Allosteric Modulators: Molecular, Cellular and In Vivo PharmacologyR01DA039942 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G., LICHTMAN, ARON H · 2016 to 2020
$2.6M
Endocannabinoid-mediated neuroprotection in models of neuroAIDS in vivoR01DA045596 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2018 to 2022
$1.9M
Investigation of endocannabinoid-mediated neuroprotection in models of neuroAIDSR21DA041903 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FITTING, SYLVIA · 2016 to 2017
$407k
NIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA039942NIDA NIH HHS R01 DA045596NIDA NIH HHS R21 DA041903NIDA NIH HHS T32 DA007244
6 · The paper itself

Abstract

While current therapeutic strategies for people living with human immunodeficiency virus type 1 (HIV-1) suppress virus replication peripherally, viral proteins such as transactivator of transcription (Tat) enter the central nervous system early upon infection and contribute to chronic inflammatory conditions even alongside antiretroviral treatment. As demand grows for supplemental strategies to combat virus-associated pathology presenting frequently as HIV-associated neurocognitive disorders (HAND), the present study aimed to characterize the potential utility of inhibiting monoacylglycerol lipase (MAGL) activity to increase inhibitory activity at cannabinoid receptor-type 1 receptors through upregulation of 2-arachidonoylglycerol (2-AG) and downregulation of its degradation into proinflammatory metabolite arachidonic acid (AA). The MAGL inhibitor MJN110 significantly reduced intracellular calcium and increased dendritic branching complexity in Tat-treated primary frontal cortex neuron cultures. Chronic MJN110 administration

Indexed as

2-arachidonoyl glycerolendocannabinoidsexcitotoxicityHIVMJN110monoacylglycerol lipaseTat

Identifiers

PMID34484091
PMCPMC8415271
OpenAlexW3194165391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.